Short answer
Altimmune, Inc. (ALT) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Richard Menziuso appointed Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026.
Altimmune, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Richard Menziuso appointed Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026
- CFO Gregory Weaver remains in role, indicating accounting leadership change without CFO turnover
- Menziuso brings 28 years of finance and accounting experience, including 12 years in public accounting
- Appointment adds biopharmaceutical controllership experience from Centessa Pharmaceuticals and Axovant Gene Therapies
- Indemnification agreement planned on substantially the same terms as other executive officers
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Altimmune, Inc. 8-K filings
Get the next ALT 8-K as it lands
Follow ALT for push alerts, or ask the research agent what this filing means.